Expression of CD20 and CD52 in ALL and frequencies of GPI-defective cells
| Case no. . | Age, y . | Sex . | WBCs, × 106/mL . | Subtype . | CD52 (MFI) . | GPI-defective, %* . | CD20 (MFI) . |
|---|---|---|---|---|---|---|---|
| 1 | 34 | F | 162 | pro B | 6 | NA | 6 |
| 2 | 18 | F | 10 | pro B | 8 | NA | 6 |
| 3 | 37 | M | 480 | pro B | 5 | NA | 4 |
| 4 | 49 | F | 258 | pro B | 7 | NA | 5 |
| 5 | 19 | M | 454 | pro B | 8 | NA | 6 |
| 6 | 47 | F | 6 | pro B | 369 | 0.02 | 6 |
| 7 | 24 | F | 63 | pro B | 335 | 0.17 | 6 |
| 8 | 20 | M | 11 | Common | 272 | 0.00 | 134 |
| 9 | 21 | F | 44 | Common | 74 | ND | 5 |
| 10 | 59 | M | 5 | Common | 34 | ND | 17 |
| 11 | 30 | M | 129 | Common | 290 | 0.01 | 313 |
| 12 | 27 | M | 48 | Common | 238 | 0.01 | 593 |
| 13 | 20 | M | 38 | Common | 167 | 0.02 | 8 |
| 14 | 37 | M | 125 | Common | 176 | 0.06 | 163 |
| 15 | 32 | M | 219 | CML-LBP (c) | 617 | 0.00 | 889 |
| 16 | 53 | M | NA | CML-LBP (c) | 193 | 0.01 | 264 |
| 17 | 23 | M | 3 | pre B | 388 | 0.00 | 1034 |
| 18 | 36 | F | 3 | pre B | 43 | ND | 11 |
| 19 | 17 | M | 20 | pre B | 91 | ND | 113 |
| 20 | 32 | F | 288 | pre B | 87 | ND | 9 |
| 21 | 18 | M | 14 | pre B | 294 | 0.02 | 4 |
| 22 | 40 | M | 19 | pre B | 280 | 0.04 | 204 |
| 23 | 24 | F | 63 | pre B | 190 | 0.40 | 128 |
| 24 | 37 | M | 59 | pre B | 137 | 4.00 | 254 |
| Normal† | 901 ± 37 | 2425 ± 134 |
| Case no. . | Age, y . | Sex . | WBCs, × 106/mL . | Subtype . | CD52 (MFI) . | GPI-defective, %* . | CD20 (MFI) . |
|---|---|---|---|---|---|---|---|
| 1 | 34 | F | 162 | pro B | 6 | NA | 6 |
| 2 | 18 | F | 10 | pro B | 8 | NA | 6 |
| 3 | 37 | M | 480 | pro B | 5 | NA | 4 |
| 4 | 49 | F | 258 | pro B | 7 | NA | 5 |
| 5 | 19 | M | 454 | pro B | 8 | NA | 6 |
| 6 | 47 | F | 6 | pro B | 369 | 0.02 | 6 |
| 7 | 24 | F | 63 | pro B | 335 | 0.17 | 6 |
| 8 | 20 | M | 11 | Common | 272 | 0.00 | 134 |
| 9 | 21 | F | 44 | Common | 74 | ND | 5 |
| 10 | 59 | M | 5 | Common | 34 | ND | 17 |
| 11 | 30 | M | 129 | Common | 290 | 0.01 | 313 |
| 12 | 27 | M | 48 | Common | 238 | 0.01 | 593 |
| 13 | 20 | M | 38 | Common | 167 | 0.02 | 8 |
| 14 | 37 | M | 125 | Common | 176 | 0.06 | 163 |
| 15 | 32 | M | 219 | CML-LBP (c) | 617 | 0.00 | 889 |
| 16 | 53 | M | NA | CML-LBP (c) | 193 | 0.01 | 264 |
| 17 | 23 | M | 3 | pre B | 388 | 0.00 | 1034 |
| 18 | 36 | F | 3 | pre B | 43 | ND | 11 |
| 19 | 17 | M | 20 | pre B | 91 | ND | 113 |
| 20 | 32 | F | 288 | pre B | 87 | ND | 9 |
| 21 | 18 | M | 14 | pre B | 294 | 0.02 | 4 |
| 22 | 40 | M | 19 | pre B | 280 | 0.04 | 204 |
| 23 | 24 | F | 63 | pre B | 190 | 0.40 | 128 |
| 24 | 37 | M | 59 | pre B | 137 | 4.00 | 254 |
| Normal† | 901 ± 37 | 2425 ± 134 |
WBC indicates white blood cells; CML-LBP (c), chronic myeloid leukemia in lymphoid blastic phase; Common, B-ALL phenotype; MFI, median fluorescence intensity; NA, not applicable; and ND, GPI cells possibly present but could not be discriminated from the bulk because of low expression levels of CD52.
Percentage of cells with a GPI-defective CD19+CD52−CD55− phenotype.
Normal CD19+ B cells from 3 healthy persons included as reference values.